Search results
Results from the WOW.Com Content Network
Reactive gastropathy is morphologically distinct entity [3] [4] that can be separated from gastritis, which by definition has a significant inflammatory component. As a reactive gastropathy may mimic a (true) gastritis symptomatically and visually in an endoscopic examination , it may incorrectly be referred to as a gastritis.
Atrophic gastritis is a process of chronic inflammation of the gastric mucosa of the stomach, leading to a loss of gastric glandular cells and their eventual replacement by intestinal and fibrous tissues.
Gastric ulcers may develop; it is unclear if they are the causes or the consequences. Intestinal metaplasia typically begins in response to chronic mucosal injury in the antrum and may extend to the body. Gastric mucosa cells change to resemble intestinal mucosa and may even assume absorptive characteristics.
Inflammation of the stomach by infection from any cause is called gastritis, and when including other parts of the gastrointestinal tract called gastroenteritis. When gastritis persists in a chronic state, it is associated with several diseases, including atrophic gastritis, pyloric stenosis, and gastric cancer.
The usual appearance of portal hypertensive gastropathy on endoscopy is a mosaic-like or reticular pattern in the mucosa. Red spots may or may not be present. The pattern is usually seen throughout the stomach. [2] A similar pattern can be seen with a related condition called gastric antral vascular ectasia (GAVE), or watermelon stomach.
Cetuximab is the first-line therapy for Ménétrier disease. [2] Cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR), and has been shown to be effective in treating Ménétrier disease. [7] Several medications have been used in the treatment of the condition, with variable efficacy.
Immune dysregulation, inflammation, and barrier dysfunction Studies on postinfectious IBS have shown that factors such as mucosal membrane permeability, the intestinal flora, and altered mucosal immune function. Ultimately leading to visceral hypersensitivity.
This medicine increases gastric mucosal prostaglandin E2, protects gastric mucosa, thereby suppresses gastric mucosal damage and increases gastric mucus secretion and gastric mucosal blood flow, to improve hemodynamic impairment, suppress inflammation and repair the gastric mucosa. It is usually used to treat gastric ulcer and improve gastric ...